291 Papers
577 Citations
Liang Liu is an academic researcher from Macau University of Science and Technology. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 34, co-authored 259 publications. Previous affiliations of Liang Liu include Guangzhou University of Chinese Medicine.
Chat about Author
Papers
Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer
Lian-Xiang Luo,Ying Li,Yuzhen Niu,Yuwei Wang,Qianqian Wang,Xing-Xing Fan,Jiahui Xu,Liang Liu,Elaine Lai-Han Leung,Xiaojun Yao,Xiaojun Yao +10 more
TL;DR: The compound 5067-0952 was identified as a potent ALK inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of ALK, subsequently blocking its downstream signaling pathway.
Patent
Novel Ginsenoside Derivative Compounds And The Use Thereof In Protection Against Ischemia/Reperfusion Injury
Jing-Rong Wang,Pei Luo,Hua Zhou,Wai In Chan,Liang Liu,Zhi-Hong Jiang +5 more
- 23 Apr 2015
TL;DR: In this paper, the ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury are described. But they do not describe the use of ginsenide derivatives in medical applications.
Patent
Combination treatment of RAS-positive diseases with PDE-δ inhibitor and direct autophagy inhibitor
Liang Liu,David C. Ward,Elaine Lai-Han Leung,Xiao Jun Yao,Vincent Kam Wai Wong,Lian-Xiang Luo +5 more
- 09 Jan 2018
TL;DR: In this paper, the authors present methods for treatment of a RAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE-6 inhibitor by combining the PDE6 inhibitor with a direct autophagy inhibitor.
Patent
Method to treat lung cancer
Liang Liu,Elaine Lai-Han Leung,Xiao-Jun Yao,Vincent Kam Wai Wong,Xi Chen +4 more
- 02 Jan 2018
TL;DR: In this paper, a method of treating lung cancer by administering a compound of formula I to a subject in need thereof is described, and a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of the formula to a patient is presented.
Patent
Transgenic model for delay-type hypersensitivity (dth) and use thereof
Liang Liu,Ting Li,Kam Wai Wong,Zhi-Hong Jiang,Hua Zhou +4 more
- 11 Feb 2015
TL;DR: In this article, an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-β C46A mutants is presented.